Quick Overview: The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker The GLP-1 drug revolution has taken the medicine world by storm. I've done several episodes on the science of GLP-1s. What is the significance of intellectual property to life science companies? What do most of the public not understand about ...

Eli Lilly Ceo We Expect - Detailed Overview & Context

The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker The GLP-1 drug revolution has taken the medicine world by storm. I've done several episodes on the science of GLP-1s. What is the significance of intellectual property to life science companies? What do most of the public not understand about ...

Photo Gallery

Eli Lilly CEO: Our pill supply can 'reach the planet'
Eli Lilly CEO: We expect to launch five new medicines in 2022
Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic
Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet it
Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Eli Lilly CEO: We see a path to an Alzheimer's disease-modifying drug
Eli Lilly CEO on Fighting Obesity, Developing New Drugs
Eli Lilly CEO on raising $1B for antibiotic research: Goal is to have two to four new antibiotics
Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result
Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored